You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
atezolizumab (Tecentriq) for NSCLC Roche Full submission 2/04/2018 Q2 2018 Q3 2018
atezolizumab (Tencentriq) Roche Full submission 4/12/2017 6/02/2018 12/03/2018
avelumab (Bavencio) Merck Serono Europe Limited / Pfizer Limited Full submission 5/02/2018 Q2 2018 Q2 2018
crizotinib (Xalkori) Pfizer Ltd Full submission 5/03/2018 Q2 2018 Q2 2018
inotuzumab ozogamicin (Besponsa) Pfizer Ltd Full submission 5/03/2018 Q2 2018 Q2 2018
letermovir (Prevymis) MSD Full submission 2/04/2018 Q2 2018 Q3 2018
lutetium 177Lu oxodotreotide (Lutathera) Advanced Accelerator Applications Full submission 2/04/2018 Q2 2018 Q3 2018
midostaurin (Rydapt) for AML Novartis Pharmaceuticals UK Ltd Full submission 5/03/2018 Q2 2018 Q2 2018
niraparib tosylate monohydrate (Zejula) Tesaro UK Ltd Full submission TBC TBC TBC
pembrolizumab (Keytruda) (cHL) MSD Full submission 4/12/2017 6/02/2018 12/03/2018
regorafenib (Stivarga) Bayer Plc Full submission 5/02/2018 Q2 2018 Q2 2018
ribociclib (Kisqali) Novartis Pharmaceuticals UK Ltd Full submission 4/12/2017 6/02/2018 12/03/2018
telotristat (Xermelo) Ipsen Ltd Full submission 5/03/2018 Q2 2018 Q2 2018
tivozanib (Fotivda) EusaPharma Full submission 2/04/2018 Q2 2018 Q3 2018

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
asparaginase (Spectrila) Medac Pharmaceuticals Abbreviated Submission N/A 6/03/2018 9/04/2018
dimethyl fumarate (Skilarence) Almirall Ltd Full submission 5/02/2018 6/03/2018 9/04/2018
ocrelizumab (Ocrevus) Roche Full submission TBC TBC TBC

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Back